Ascendis Pharma (ASND)
(Real Time Quote from BATS)
$153.99 USD
+0.56 (0.37%)
Updated Sep 20, 2024 11:10 AM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ASND 153.99 +0.56(0.37%)
Will ASND be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ASND based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ASND
Ascendis Soars on Encouraging Data From Dwarfism Drug Study
Ascendis Pharma (ASND) Moves 17.1% Higher: Will This Strength Last?
ASND: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ascendis (ASND) Up on FDA Nod for Hormone Therapy Yorvipath
Ascendis Pharma (ASND) Surges 8.7%: Is This an Indication of Further Gains?
FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing
Other News for ASND
Janus Henderson Global Life Sciences Fund Q2 2024 Commentary
Ascendis Pharma prices $300M equity offering
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
Eyconis, Inc. Announces Appointment of Dr. Mark J. Bachleda as Chief Executive Officer and Member of the Board of Directors
Ascendis Pharma 2M share Secondary priced at $150.00